MARKET

BHC

BHC

Bausch Health Companies Inc
NYSE

Real-time Quotes | Nasdaq Last Sale

27.76
-0.27
-0.96%
Closed 16:44 05/06 EDT
OPEN
27.71
PREV CLOSE
28.03
HIGH
27.95
LOW
27.13
VOLUME
506
TURNOVER
--
52 WEEK HIGH
34.80
52 WEEK LOW
14.86
MARKET CAP
9.95B
P/E (TTM)
-9.7110
1D
5D
1M
3M
1Y
5Y
Bausch Health Announces Participation In Upcoming Investor Conferences
LAVAL, Quebec, May 6, 2021 /PRNewswire via COMTEX/ -- LAVAL, Quebec, May 6, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch...
PR Newswire - PRF · 1d ago
Bausch's (BHC) Q1 Earnings Beat Estimates, Revenues Miss
Zacks · 1d ago
DJ Bausch Health Companies Inc. Is Maintained at Outperform by RBC Capital
Dow Jones · 1d ago
DJ Bausch Health Companies Inc. Price Target Cut to $41.00/Share From $42.00 by RBC Capital
Dow Jones · 1d ago
Bausch Health Companies (BHC) Receives a Hold from BMO Capital
BMO Capital analyst Gary Nachman maintained a Hold rating on Bausch Health Companies (BHC) today and set a price target of $27.00. The company's shares
SmarterAnalyst · 1d ago
Health Canada Issues Notice of Compliance (NOC) for Bausch Health's BRYHALI
CNW Group · 2d ago
64 Biggest Movers From Yesterday
Gainers
Benzinga · 2d ago
--RBC Trims Price Target on Bausch Health to $41 From $42, Maintains Outperform Rating
MT Newswires · 2d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BHC. Analyze the recent business situations of Bausch Health Companies Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 17 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average BHC stock price target is 35.25 with a high estimate of 55.00 and a low estimate of 20.00.
EPS
Institutional Holdings
Institutions: 514
Institutional Holdings: 247.13M
% Owned: 68.96%
Shares Outstanding: 358.40M
TypeInstitutionsShares
Increased
96
19.66M
New
59
12.82M
Decreased
116
17.15M
Sold Out
40
5.29M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.01%
Pharmaceuticals & Medical Research
-0.29%
Key Executives
Chairman/Chief Executive Officer/Director
Joseph Papa
Chief Financial Officer/Executive Vice President
Paul Herendeen
Corporate Executive
Thomas Appio
Corporate Executive
Joseph Gordon
Corporate Executive
Robert Spurr
Executive Vice President/General Counsel
Christina Ackermann
Independent Director
Richard DeSchutter
Senior Vice President - Finance/Chief Accounting Officer/Controller
Sam Will
Lead Director
Thomas Ross
Independent Director
Richard De Schutter
Independent Director
D. Robert Hale
Independent Director
Brett Icahn
Independent Director
Argeris Karabelas
Independent Director
Sarah Kavanagh
Independent Director
Steven Miller
Independent Director
John Paulson
Independent Director
Robert Power
Independent Director
Andrew von Eschenbach
Independent Director
Russel Robertson
Independent Director
Andrew Charles von Eschenbach
Independent Director
Amy Wechsler
Declaration Date
Dividend Per Share
Ex-Div Date
09/22/2010
Dividend USD 16.77
09/23/2010
05/05/2010
Dividend USD 0.095
05/31/2010
02/24/2010
Dividend USD 0.09
03/04/2010
11/04/2009
Dividend USD 0.09
11/30/2009
08/06/2009
Dividend USD 0.09
08/28/2009
05/06/2009
Dividend USD 0.09
05/13/2009
02/26/2009
Dividend USD 0.375
03/06/2009
11/06/2008
Dividend USD 0.375
12/19/2008
08/13/2008
Dividend USD 0.375
08/21/2008
05/08/2008
Dividend USD 0.375
05/20/2008
03/13/2008
Dividend USD 0.375
03/25/2008
11/08/2007
Dividend USD 0.375
11/16/2007
08/08/2007
Dividend USD 0.375
08/16/2007
05/10/2007
Dividend USD 0.375
05/17/2007
03/15/2007
Dividend USD 0.375
03/22/2007
12/06/2006
Dividend USD 0.5
01/08/2007
11/09/2006
Dividend USD 0.125
11/20/2006
08/03/2006
Dividend USD 0.0775
08/15/2006
05/11/2006
Dividend USD 0.125
05/18/2006
03/23/2006
Dividend USD 0.125
04/05/2006
02/28/2006
Dividend USD 0.0775
03/14/2006
11/15/2005
Dividend USD 0.5
11/28/2005
11/04/2005
Dividend USD 0.0775
11/15/2005
08/04/2005
Dividend USD 0.0775
08/17/2005
03/10/2005
Dividend USD 0.0775
04/11/2005
12/29/2004
Dividend USD 0.0775
01/10/2005
06/30/2004
Dividend USD 0.0775
07/12/2004
03/03/2004
Dividend USD 0.0775
04/12/2004
12/19/2003
Dividend USD 0.0775
01/12/2004
01/04/2001
Dividend USD 0.0725
01/10/2001
10/04/1999
Dividend USD 0.07
10/08/1999
06/22/1999
Dividend USD 0.07
07/12/1999
03/22/1999
Dividend USD 0.07
04/12/1999
01/12/1999
Dividend USD 0.06
01/20/1999
About BHC
Bausch Health Companies Inc, formerly Valeant Pharmaceuticals International Inc, is a Canada-based company that develops, manufactures and markets a range of branded and generic pharmaceuticals, medical devices and over-the-counter products. It primarily develops products in the therapeutic areas of eye health, gastroenterology and dermatology. Its dermatology products treat a range of conditions, including actinic keratosis, acne, atopic dermatitis, psoriasis and other dermatoses. It also offers a selection of aesthetic medical devices that address a variety of conditions, including facial wrinkles, acne, pigmentation conditions and laser hair removal, among others. The gastrointestinal (GI) segment offers products that treat GI and hepatologic conditions, including hepatic encephalopathy, irritable bowel syndrome with diarrhea and ulcerative colitis, among others. Its eye health products are marketed in the following categories: Contact Lens, Pharmaceutical Products and Surgical.

Webull offers kinds of Bausch Health Companies Inc stock information, including NYSE:BHC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BHC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BHC stock methods without spending real money on the virtual paper trading platform.